Navigation Links
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Date:10/16/2009

at the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

US.RAS.09.09.009

Contact: Madeline Malia, sanofi-aventis U.S., (908) 981-5687, madeline.malia@sanofi-aventis.com

SOURCE sanofi-aventis


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
2. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
3. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
4. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
5. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
6. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
7. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
8. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
9. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
10. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
11. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2012)... -- PLC Systems Inc. (OTCBB: PLCSF), a company focused ... results for the three-month period ended March 31, ... operations, since PLC completed the sale of its ... the first quarter of 2011.  Results from the ... all periods presented. First quarter 2012 ...
(Date:5/15/2012)... 15, 2012 BiO2 Medical, Inc. a ... in San Antonio, Texas, and R&D and manufacturing ... has received CE Mark approval for the Angel™ ... permanently attached to a central venous catheter (CVC) ... in critically ill patients. This novel IVC filter/CVC ...
(Date:5/15/2012)... May 15, 2012  Boston Scientific Corporation ... the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium ... treating de novo coronary artery ... PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent System ...  The trial reported one-year clinical and six-month ...
Breaking Medicine Technology:PLC Systems Reports First Quarter 2012 Results 2PLC Systems Reports First Quarter 2012 Results 3PLC Systems Reports First Quarter 2012 Results 4PLC Systems Reports First Quarter 2012 Results 5PLC Systems Reports First Quarter 2012 Results 6One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6Cyberonics to Present at JMP Securities 4th Annual Healthcare Focus Conference 14268 1Cyberonics to Present at JMP Securities 4th Annual Healthcare Focus Conference 14268 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 1Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 10101 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 1Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 2Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 3Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 5Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 6Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 7Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 8Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 9Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 10Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 11Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 12Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 13Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 14Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 15Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 16Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 17
... Presented at International Conference on Malignant ... Shows Dose Dependent Single Agent Activity, BETHESDA, ... biopharmaceutical company developing novel, proprietary antibodies,for the treatment ... update of an ongoing phase 1 clinical trial ...
... Discuss Clinical, Financial ... DUBLIN, Ohio, June 4 In a move that ... of,hospital-acquired infections (HAIs), Cardinal Health announced today that,it will ... will focus on the leadership and operational issues that ...
Other Medicine Technology:Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 2Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 3Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 4Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma 5Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 2Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 3Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections 4
(Date:5/16/2012)... issue of BioResearch Open Access , a ... today by Mary Ann Liebert, Inc., publishers. The ... broad range of scientific topics including but not ... and biomaterials, regenerative medicine, stem cells, gene therapy, ... The first issue is available on the ...
(Date:5/16/2012)... (HealthDay News) -- Heart palpitations and high blood pressure ... disorder called atrial fibrillation, a new study reports. ... stroke and death. It was already known that high ... but, according to the researchers, this is the first ... palpitations, which are commonly felt as a rapid or ...
(Date:5/16/2012)... myeloma patients are better equipped to halt progression of ... following a stem cell transplant, according to a study ... Science University Knight Cancer Institute. , The study, published ... found a 63 percent reduction in the risk of ... patients that were treated with lenalidomide maintenance therapy. , ...
(Date:5/15/2012)... Carina Storrs HealthDay Reporter , , TUESDAY, May ... to begin in London this summer, a new study ... an important public health message: Reducing air pollution levels ... Four years ago, an international team of ... the 2008 Olympics, to see what health effects those ...
(Date:5/15/2012)... (HealthDay News) -- Researchers have identified gene variants ... they say their findings could help identify patients ... The researchers, from the University of California-Los Angeles, ... develop new therapies. Parkinson,s disease is a ... rigidity. The researchers followed 233 patients for ...
Breaking Medicine News(10 mins):Health News:Premier issue of BioResearch Open Access launched by Mary Ann Liebert Inc. publishers 2Health News:Palpitations May Signal Future Heart Rhythm Problem 2Health News:Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant 2Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 2Health News:Beijing's Olympic Smog Shows Pollution's Effect on Health 3Health News:Genes Might Be Key to Parkinson's Spread 2
... the third phase of clinical trail conducted by researchers at ... weekly dose of erythropoietin //(EPO) is a very effective treatment ... ,EPO is a natural hormone that stimulates production ... cell (RBC) transfusions in these children. This is the ...
... in New York City has discovered that chronic pain occurs ... his colleagues were studying chronic pain at the molecular and ... occurs and the neurons becomes excited and begin to send ... when the stimulus is removed the nerves become dormant and ...
... exchange agreement with an Israeli company to introduce its ... technology enabled patients to be monitored anywhere and at ... telephones, Heartline Managing Director Dr Selva Annamalai told reporters ... doctor, 24 hours a day from anywhere, who could ...
... condition, chronic widespread pain is often difficult to ... depression and poor sleep.// ,A link between ... FM like symptoms after treatment with cytokine interleukin ... contradictory results. A new study published in the ...
... Cambodia in the Aids prevention initiatives have been applauded, ... of condoms.// ,Professor K. Satkunantham, the director of ... 100 per cent condom use programmes in Thailand and ... ,In the 25 years of the existence ...
... French teenage girl was admitted appearing unsteady and mentally sluggish ... doctors. // ,In addition it was found that the ... were puzzled because there appeared to be no family history ... in this week's New England Journal of Medicine. ...
Other Medicine News:Health News:EPO Effective For Cancer Patients Suffering From Anemia 2Health News:Insufficent Anti-inflammatoy Proteins Leads to Chronic Pain 2Health News:Teens High on Mothballs 2
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ... tip style, size and angle required for ...
... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ... size and angle required for large and ...
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
Medicine Products: